SCHEMBL6594792

SCHEMBL6594792

C1#Cc2ccccc2C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29283240 0.80 MAOA (0.35)
SCHEMBL20477699 0.76 TSHR (0.42)
SCHEMBL327799 0.74 TSHR (0.43)
SCHEMBL31251596 0.74 TSHR (0.43)
SCHEMBL2144679 0.74
SCHEMBL9630603 0.74
SCHEMBL20477815 0.74 TSHR (0.38)
SCHEMBL4121654 0.72
SCHEMBL1098772 0.69 TSHR (0.50)
Fluoride SCHEMBL31607698 0.67 TSHR (0.48)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3303328-B1 AMINOESTER DERIVATIVES CHIESI FARM SPA (IT) 2019-03-20 EP claimed
EP-3152201-B1 AMINOESTER DERIVATIVES CHIESI FARM SPA (IT) 2018-08-29 EP claimed
EP-1036062-B1 HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE (MMP) INHIBITORS PFIZER LTD (GB) 2004-01-02 EP claimed
EP-0099057-B1 N-ACYL DERIVATIVES OF PEPTIDES, THEIR MANUFACTURE AND USE IN COMBATING DISEASES AND MEANS THEREFOR BASF Aktiengesellschaft (DE) 1987-10-14 EP claimed
US-20160067361-A1 ORGAN PROTECTION IN PSMA-TARGETED RADIONUCLIDE THERAPY OF PROSTATE CANCER MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) 2016-03-10 US disclosed